HIF1A and myeloid sarcoma: Clinical and preclinical studies (7, 35), including ours (36), indicate the involvement of the HIF-1 signaling pathway in MS, and together, these findings suggest that inhibition of HIF-1 may provide a new strategy for the treatment of MS.